U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H14N2O6S3.2Na
Molecular Weight 448.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE SODIUM

SMILES

[Na+].[Na+].[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS([O-])=O)C=C2

InChI

InChIKey=AZBNFLZFSZDPQF-UHFFFAOYSA-L
InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C14H14N2O6S3
Molecular Weight 402.466
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

1947
100
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Primary
Approved
8583
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Primary
Approved
8583
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
REVIEW
https://doi.org/10.1016/S0099-5428(08)60377-9
330 mg single, oral
dose: 330 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DAPSONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Nausea, Weakness...
Other AEs:
Nausea
Weakness
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Malaise...
Other AEs:
Malaise
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Disc. AE: Hemolytic anemia, Methemoglobinemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia
Methemoglobinemia
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
Health Status: unhealthy
Age Group: 52 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Disc. AE: Erythema facial, Erythema...
AEs leading to
discontinuation/dose reduction:
Erythema facial
Erythema
Furunculosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
AEs

AEs

AESignificanceDosePopulation
Nausea
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Weakness
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Malaise
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Hemolytic anemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Methemoglobinemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Erythema facial Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
Health Status: unhealthy
Age Group: 52 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Erythema Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
Health Status: unhealthy
Age Group: 52 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Furunculosis Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
Health Status: unhealthy
Age Group: 52 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Sourcing

Sourcing

Vendor/AggregatorIDURL
AAA Chemistry
AR-1A9274
ABI Chem
AC1L1K5Q
ABI Chem
AC1Q6YP0
BOC Sciences
144-75-2
ChemTik
CTK4C4202
Compound Cloud
5351
Compound Cloud
8954
eMolecules
260190822
Kingston Chemistry
KST-1A1474
MuseChem
M069826
NCI Plated 2007
27222
NovoSeek
5351
ZINC
ZINC000018268128
http://zinc15.docking.org/substances/ZINC000018268128
PubMed

PubMed

TitleDatePubMed
Impact of glycemic control on the incidence of acute kidney injury in critically ill patients: a comparison of two strategies using the RIFLE criteria.
2010-06
Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus.
2008-04-20
Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue.
2007-03-15
Diastereomerically and enantiomerically pure 2,3-disubstituted pyrrolidines from 2,3-aziridin-1-ols using a sulfoxonium ylide: a one-carbon homologative relay ring expansion.
2007-02-21
Avoid, attack or do both? Behavioral and physiological adaptations in natural enemies faced with novel hosts.
2005-11-04
Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS).
2005
Asymmetric synthesis of unsaturated, fused bicyclic proline analogues through amino alkylation of cyclic bis(allylsulfoximine)titanium complexes and migratory cyclization of delta-amino alkenyl aminosulfoxonium salts.
2003-10-29
Asymmetric synthesis of anti-homopropargylic alcohols from aldehydes and chiral sulfonimidoyl substituted bis(allyl)titanium complexes through generation and elimination of novel chiral alkylidenecarbene (dimethylamino)sulfoxonium ylides.
2002-09-04
p-Sulfooxyphenylpyruvic acid from the red macro alga Ceratodictyon spongiosum and its sponge symbiont Haliclona cymaeformis.
2002-06

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:57 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:57 GMT 2025
Record UNII
57OWB0Q221
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFOXONE SODIUM
MI   ORANGE BOOK  
Common Name English
ALDESULFONE SODIUM
INN   MART.   WHO-DD  
INN  
Preferred Name English
DIASONE SODIUM
Brand Name English
ALDESULPHONE SODIUM
Common Name English
NSC-27222
Code English
SULFOXONE SODIUM [ORANGE BOOK]
Common Name English
ALDESULFONE SODIUM [MART.]
Common Name English
DISODIUM (SULFONYLBIS(P-PHENYLENEIMINO))DIMETHANESULFINATE
Common Name English
SULFOXONE SODIUM [MI]
Common Name English
Aldesulfone sodium [WHO-DD]
Common Name English
METHANESULFINIC ACID, (SULFONYLBIS(1,4-PHENYLENEIMINO))BIS-, DISODIUM SALT
Common Name English
aldesulfone sodium [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
WHO-ATC J04BA03
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
Code System Code Type Description
WIKIPEDIA
ALDESULFONE SODIUM
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
DRUG BANK
DB01145
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
MERCK INDEX
m10368
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY Merck Index
SMS_ID
100000087868
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
NSC
27222
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
EVMPD
SUB05304MIG
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
ChEMBL
CHEMBL1570
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
PUBCHEM
8954
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
INN
971
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
MESH
C036115
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
CAS
144-75-2
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
NCI_THESAURUS
C66574
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023623
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
FDA UNII
57OWB0Q221
Created by admin on Mon Mar 31 17:35:57 GMT 2025 , Edited by admin on Mon Mar 31 17:35:57 GMT 2025
PRIMARY
Related Record Type Details
Structure of SULFOXONE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of SULFOXONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966